病灶内及病灶周围注射重组人表皮生长因子与亲水胶体治疗静脉性溃疡的成本效果分析:哥伦比亚背景
该研究采用马尔可夫模型,从哥伦比亚卫生系统视角,比较病灶内及病灶周围注射重组人表皮生长因子(rhEGF)与亲水胶体治疗无感染慢性静脉功能不全患者的5年成本效果。结果显示rhEGF单价更高,但愈合更快,每增加一个质量调整生命年成本更低,因此更具成本效果。
要点
- rhEGF单位成本高于亲水胶体,但8至12周内可愈合溃疡,复杂病例亦有效。
- 亲水胶体平均需29.5周愈合,复杂病例可达46周。
- rhEGF每增加一个质量调整生命年的成本更低,更具成本效果。
核心结论
- 基于成本效果分析,rhEGF是哥伦比亚治疗静脉性溃疡优于亲水胶体的替代方案,更经济且能提升患者生活质量并优化资源利用。
研究设计与样本
- 采用马尔可夫模型进行5年成本效果分析,视角为哥伦比亚卫生系统,纳入年龄>18岁确诊慢性静脉功能不全且无感染的患者,临床研究用于计算上皮化、感染、复发和死亡的概率。
主要发现
- rhEGF单位成本高于亲水胶体,但8至12周内可有效愈合溃疡,复杂病例亦有效。
- 亲水胶体平均需29.5周愈合,复杂病例需≤46周。
- rhEGF每增加一个质量调整生命年的成本更低,更具成本效果。
临床怎么用
- 作者认为,基于成本效果分析,rhEGF是哥伦比亚治疗静脉性溃疡优于亲水胶体的替代方案。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To perform a comparative analysis of health care expenses and outcomes in response to the question: What is the cost-effectiveness of intralesional and perilesional recombinant human epidermal growth factor (rhEGF) compared with hydrocolloid therapy in patients diagnosed with chronic venous insufficiency without infection in Colombia? METHODS: A Markov model was used to determine cost effectiveness over a 5-year period, considering the perspective of the health system in Colombia. The study included patients aged >18 years diagnosed with chronic venous insufficiency and used clinical studies to calculate the probabilities of epithelialization, infection, recurrence, and mortality. RESULTS: RhEGF is more expensive per unit than hydrocolloids, but it is proven to be effective at healing ulcers in 8 to 12 weeks, even in complex cases. Hydrocolloids, in contrast, typically require 29.5 weeks on average, and ≤46 weeks for complex cases. Despite the cost, rhEGF is more cost effective because it achieves results comparable with hydrocolloid therapy at a lower cost per additional quality-adjusted life-year. CONCLUSIONS: Based on cost-effectiveness analysis, rhEGF is a superior alternative to hydrocolloids for treating venous ulcers in Colombia. Not only is it more affordable, but it also enhances patients' quality of life and streamlines the health care system's resource use.
引用
- Cacua Sánchez MT, Botero AM, Moreno-Mattar O, et al. Cost-effectiveness analysis of intralesional and perilesional recombinant human epidermal growth factor vs hydrocolloid therapy in venous ulcer treatment in the Colombian context. J Vasc Surg Venous Lymphat Disord. 2023. PMID: 38145819. doi:10.1016/j.jvsv.2023.101745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。